Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AZ, Palatin Amend R&D Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

AZ, Palatin Amend R&D Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca and Palatin have amended their January 2007 global licensing and research agreement to discover, develop and commercialize compounds targeting melanocortin receptors.
   
Under the amendment, Palatin has agreed to license additional compounds and associated intellectual property to AZ. Palatin will receive development and regulatory milestone payments if any additional compound advances into human clinical trials, as well as sales milestone payments and royalties if any additional compound is commercialized. AZ is responsible for product commercialization, discovery and development costs.
   
“The collaboration between AstraZeneca and Palatin is very productive and has resulted in valuable scientific and technical advances,” stated Dr. Trevor Hallam, Palatin’s executive vice president for R&D. “We look forward to initiating human clinical trials for obesity.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics